MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
Canada • Toronto Stock Exchange • TSX:DR • CA58457V5036
16.2 CAD
-0.14 (-0.86%)
Last: Feb 6, 2026, 07:00 PM
Overall DR gets a fundamental rating of 7 out of 10. We evaluated DR against 14 industry peers in the Health Care Providers & Services industry. DR gets an excellent profitability rating and is at the same time showing great financial health properties. DR is cheap, but on the other hand it scores bad on growth. These ratings would make DR suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year DR was profitable.
- DR had a positive operating cash flow in the past year.
- Of the past 5 years DR 4 years were profitable.
- Each year in the past 5 years DR had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of DR (30.18%) is better than 92.86% of its industry peers.
- DR has a better Return On Equity (94.43%) than 100.00% of its industry peers.
- DR has a better Return On Invested Capital (15.42%) than 92.86% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for DR is significantly above the industry average of 7.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROIC | 15.42% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
- The Profit Margin of DR (31.60%) is better than 92.86% of its industry peers.
- In the last couple of years the Profit Margin of DR has grown nicely.
- DR's Operating Margin of 15.59% is amongst the best of the industry. DR outperforms 100.00% of its industry peers.
- DR's Operating Margin has been stable in the last couple of years.
- The Gross Margin of DR (63.75%) is better than 85.71% of its industry peers.
- In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DR is creating value.
- Compared to 1 year ago, DR has less shares outstanding
- DR has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, DR has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 1.40, we must say that DR is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.40, DR is in the better half of the industry, outperforming 64.29% of the companies in the same industry.
- The Debt to FCF ratio of DR is 2.05, which is a good value as it means it would take DR, 2.05 years of fcf income to pay off all of its debts.
- DR's Debt to FCF ratio of 2.05 is amongst the best of the industry. DR outperforms 92.86% of its industry peers.
- DR has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
- DR has a Debt to Equity ratio (1.02) which is comparable to the rest of the industry.
- Although DR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Altman-Z | 1.4 |
ROIC/WACC1.82
WACC8.47%
2.3 Liquidity
- DR has a Current Ratio of 1.79. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
- With an excellent Current ratio value of 1.79, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- A Quick Ratio of 1.67 indicates that DR should not have too much problems paying its short term obligations.
- DR has a better Quick ratio (1.67) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 60.81% over the past year.
- The Revenue for DR has decreased by -41.68% in the past year. This is quite bad
- DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
3.2 Future
- DR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.76% yearly.
- The Revenue is expected to decrease by -7.10% on average over the next years.
EPS Next Y24.91%
EPS Next 2Y15.15%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 9.94, which indicates a very decent valuation of DR.
- Based on the Price/Earnings ratio, DR is valued cheaper than 85.71% of the companies in the same industry.
- DR is valuated cheaply when we compare the Price/Earnings ratio to 27.92, which is the current average of the S&P500 Index.
- DR is valuated reasonably with a Price/Forward Earnings ratio of 9.50.
- DR's Price/Forward Earnings ratio is rather cheap when compared to the industry. DR is cheaper than 85.71% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of DR to the average of the S&P500 Index (27.78), we can say DR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.94 | ||
| Fwd PE | 9.5 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, DR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
- 85.71% of the companies in the same industry are more expensive than DR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.37 | ||
| EV/EBITDA | 4.71 |
4.3 Compensation for Growth
- DR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y15.15%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
- DR has a Yearly Dividend Yield of 2.39%.
- DR's Dividend Yield is a higher than the industry average which is at 1.35.
- DR's Dividend Yield is a higher than the S&P500 average which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.39% |
5.2 History
- The dividend of DR decreases each year by -19.91%.
- DR has been paying a dividend for at least 10 years, so it has a reliable track record.
- DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
- DR pays out 6.72% of its income as dividend. This is a sustainable payout ratio.
DP6.72%
EPS Next 2Y15.15%
EPS Next 3Y10.76%
TSX:DR (2/6/2026, 7:00:00 PM)
16.2
-0.14 (-0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11
Inst Owners11.96%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap292.41M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts40
Price Target16.58 (2.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.39% |
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.63%
EPS NY rev (1m)-6.94%
EPS NY rev (3m)-5.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.94 | ||
| Fwd PE | 9.5 | ||
| P/S | 0.83 | ||
| P/FCF | 4.37 | ||
| P/OCF | 4.02 | ||
| P/B | 2.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.71 |
EPS(TTM)1.63
EY10.06%
EPS(NY)1.71
Fwd EY10.53%
FCF(TTM)3.7
FCFY22.87%
OCF(TTM)4.03
OCFY24.85%
SpS19.51
BVpS6.53
TBVpS-0.86
PEG (NY)0.4
PEG (5Y)N/A
Graham Number15.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROCE | 18.66% | ||
| ROIC | 15.42% | ||
| ROICexc | 19.71% | ||
| ROICexgc | 46.81% | ||
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% | ||
| FCFM | 18.99% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 25.03% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 93.1% | ||
| Profit Quality | 60.09% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.4 |
F-Score6
WACC8.47%
ROIC/WACC1.82
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y24.91%
EPS Next 2Y15.15%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year4.04%
EBIT Next 3Y2.39%
EBIT Next 5YN/A
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.
Can you provide the valuation status for MEDICAL FACILITIES CORP?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
What is the expected EPS growth for MEDICAL FACILITIES CORP (DR.CA) stock?
The Earnings per Share (EPS) of MEDICAL FACILITIES CORP (DR.CA) is expected to grow by 24.91% in the next year.
How sustainable is the dividend of MEDICAL FACILITIES CORP (DR.CA) stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.